Statins linked to initial increase in polyneuropathy risk in diabetes: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-10-07 12:30 GMT | Update On 2020-10-08 08:55 GMT

Denmark: Statin therapy does not mitigate or increase the risk of diabetic polyneuropathy (DPN) in type 2 diabetes (T2D) patients, according to a recent study in the journal Diabetes Care. However, during the first year, there was a slightly increased DPN risk among new users but it receded after >2 years of the study.

Owing to lipid-lowering and anti-inflammatory effects statins may reduce diabetic polyneuropathy (DPN) risk but also, their use has been associated with neurotoxicity. Frederik P. Kristensen, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark, and colleagues examined whether statin therapy affects the risk of DPN.

The researchers identified all Danish patients with incident type 2 diabetes during 2002–2016. The initiation of statin in new users was done between 180 days before and 180 days after their first diabetes record. Prevalent users had initiated statins before that period. Patients were followed for incident diabetic polyneuropathy (DPN) using validated hospital diagnosis codes, starting 180 days after their first diabetes record

The study cohort consiaited of 59,255 (23%) new users, 75,528 (29%) prevalent users, and 124,842 (48%) nonusers; median follow-up time was 6.2 years.

Key findings of the study include:

The incidence rate of DPN events per 1,000 person-years was similar in new users (4.0), prevalent users (3.8) and nonusers (3.8).
The aHR for DPN was 1.05 in new users and 0.97 in prevalent users compared with statin nonusers.
New users had a slightly increased DPN risk during the first year (1.31), which vanished after >2 years of follow-up.
Findings were similar in on-treatment and propensity score-matched analyses and with additional adjustment for pretreatment blood lipid levels.

"Statin therapy is unlikely to increase or mitigate diabetic polyneuropathy (DPN) risk in patients with type 2 diabetes, although a small acute risk of harm cannot be excluded," concluded the authors.

"Statin Therapy and Risk of Polyneuropathy in Type 2 Diabetes: A Danish Cohort Study," is published in the journal Diabetes Care.

DOI: https://care.diabetesjournals.org/content/early/2020/09/29/dc20-1004

Article Source : Diabetes Care

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Statins linked to initial increase in polyneuropathy risk in diabetes: Study

Similar News

Low hemoglobin glycation index Linked to Higher Mortality in Critically Ill Patients: Study

Normal BMI Doesn’t Mean Low Risk: Study Links Diabetes to Fatty Liver in Lean Individuals

Lower Irisin Levels Linked to Diabetic Nephropathy Progression in T2DM: Study

Artificially Sweetened Drinks in Pregnancy Linked to Higher Gestational Diabetes Risk: Study

Hypoglycaemia Awareness Key to Predicting Severe Events in Type 1 Diabetes, Study Shows

AIP associated with risk of developing T2DM in women with gestational diabetes history: Study

Higher Semaglutide Doses Safely Boost Weight Loss and Health in Adults with Obesity, Confirm Two Clinical Trials

Study Links Metabolic Syndrome to Adverse Coronary Plaque Profiles in T2DM